Evidence map›Paper›PMID 34016623›Full record

ArticleCancer research2021

Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks.

Ishwar N Kohale, Danielle M Burgenske, Ann C Mladek, Katrina K Bakken, Jenevieve Kuang, Judy C Boughey, Liewei Wang, Jodi M Carter, Eric B Haura, Matthew P Goetz and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 37 citations in OpenAlex.

  1. Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Critical role of cell competition in gliomagenesis.bioRxiv : the preprint server for biology · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Ishwar N KohaleDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0001-8225-1740
Danielle M BurgenskeDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Ann C MladekDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Katrina K BakkenDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Jenevieve KuangKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Judy C BougheyDepartment of Surgery, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0003-3820-3228
Liewei WangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
Jodi M CarterDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Eric B HauraDepartment of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Matthew P GoetzDepartment of Oncology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-4383-270X
Jann N SarkariaDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Forest M WhiteDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts. fwhite@mit.edu.
Mayo Clinic · USPrecision for Medicine (United States) · USMoffitt Cancer Center · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
The MIT Superfund Research Program: A Systems Approach for the Protection of Human Health from Hazardous ChemicalsP42ES027707 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Bevin P. Engelward · 2017 to 2026
$22.2M
Trans Network ProjectU54CA210180 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WHITE, FOREST M · 2016 to 2020
$10.2M
Micro-invasive biochemical sampling of brain interstitial fluid for investigating neural pathologyR01EB027717 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CIMA, MICHAEL J, LANGER, ROBERT SAMUEL · 2020 to 2023
$2.5M
Identification of adaptive response mechanisms in breast cancer by information theory and proteomicsU01CA238720 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KRAVCHENKO-BALASHA, NATALY, WHITE, FOREST M · 2019 to 2023
$2.0M
NCI NIH HHS P30 CA014051NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA116201NCI NIH HHS U01 CA238720NCI NIH HHS U54 CA210180NIBIB NIH HHS R01 EB027717NIEHS NIH HHS P42 ES027707
6 · The paper itself

Abstract

Human tissue samples commonly preserved as formalin-fixed paraffin-embedded (FFPE) tissues after diagnostic or surgical procedures in the clinic represent an invaluable source of clinical specimens for in-depth characterization of signaling networks to assess therapeutic options. Tyrosine phosphorylation (pTyr) plays a fundamental role in cellular processes and is commonly dysregulated in cancer but has not been studied to date in FFPE samples. In addition, pTyr analysis that may otherwise inform therapeutic interventions for patients has been limited by the requirement for large amounts of frozen tissue. Here we describe a method for highly sensitive, quantitative analysis of pTyr signaling networks, with hundreds of sites quantified from one to two 10-μm sections of FFPE tissue specimens. A combination of optimized magnetic bead-based sample processing, optimized pTyr enrichment strategies, and tandem mass tag multiplexing enabled in-depth coverage of pTyr signaling networks from small amounts of input material. Phosphotyrosine profiles of flash-frozen and FFPE tissues derived from the same tumors suggested that FFPE tissues preserve pTyr signaling characteristics in patient-derived xenografts and archived clinical specimens. pTyr analysis of FFPE tissue sections from breast cancer tumors as well as lung cancer tumors highlighted patient-specific oncogenic driving kinases, indicating potential targeted therapies for each patient. These data suggest the capability for direct translational insight from pTyr analysis of small amounts of FFPE tumor tissue specimens. SIGNIFICANCE: This study reports a highly sensitive method utilizing FFPE tissues to identify dysregulated signaling networks in patient tumors, opening the door for direct translational insights from FFPE tumor tissue banks in hospitals.

Indexed as

Evaluation Studies as TopicFormaldehydeHumansPhosphorylationProteomicsSignal TransductionFormaldehyde

Identifiers

PMID34016623
PMCPMC8286342
OpenAlexW3161061298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.